-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
IASLC Atlas of PD-L1 Testing in Lung Cancer
-
Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization
By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive […]